Skip to content
Food and Drug Administration (FDA) Commissioner Martin A. Makary, M.D., sat down with the Biotechnology Innovation Organization (BIO) President and CEO John F. Crowley […]
BIO 2025: Commissioner Martin Makary, M.D., discusses vision for FDA Read More »
Public health advocates are reevaluating the vaccine landscape, revisiting long-held assumptions about vaccine policy during both public health emergencies and periods of relative calm.
BIO 2025: How do we talk about vaccines now? Read More »
Day 1 of BIO 2025 was all about collaboration: how industry can collaborate with the U.S. government to advance biodefense, how collaboration is key
BIO 2025: A few highlights from Day 1 Read More »
Biotech’s contribution to America’s biodefense can only be supported through public-private partnerships, but the public sector must provide adequate support and private actors need
BIO 2025: A strong biodefense requires government-industry partnerships Read More »
From drug discovery to clinical trials, AI is being used, studied, refined, and advanced as a means to slingshot biotech innovations into the future
BIO 2025: AI Summit highlights role of collaboration in reaching the next frontier Read More »
The 2025 BIO International Convention, hosted by the Biotechnology Innovation Organization (BIO), opens June 16 in Boston, bringing together over 20,000 industry leaders from
Welcome to BIO 2025: The world can’t wait. Read More »
The One Big Beautiful Bill Act – the “reconciliation bill” being considered by Congress – features policies that are crucial for driving American innovation.
America, for decades, has been the undisputed global leader when it comes to innovative drug development. But this leadership is now at risk. “We
BIO Coffee Chat: ORPHAN Cures Act key to fighting rare disease Read More »
Forty-five years ago, the Bayh-Dole Act enabled greater public-private partnership, supercharging U.S. innovation and helping make America a leader in biotech. The Bayh-Dole Coalition
Bayh-Dole Coalition promotes a law that supercharged innovation Read More »
In April 2025, the Department of Health and Human Services (HHS) announced it would disband the Advisory Committee on Heritable Disorders in Newborns and
Patient’s mother advocates for newborn screening program reform Read More »
